LifeGene (LifeGene)

The ultimate objective of LifeGene health is to improve public health through providing an open resource to researchers. There will be a focus on disease etiology and everyday health problems. Growing health concerns, e.g. obesity, diabetes, allergies, psychiatric disorders, will be addressed. Susceptibility to common infections and the underlying mechanisms for infections being risk factors in development of chronic disease will be studied.

Study features will be:

  • Ascertaining a cohort of at least 200 000 Swedes.
  • Repeated assessment of in depth exposure information through electronic means (web, cell-phones, digital paper and TV, etc).
  • Repeated surveillance of morbidity through electronic means, including algorithm based assessment of diagnoses for outcomes not typically reported in national health registers, quality registers or ascertained via hospital discharge (e.g. acute infections, psychiatric disorders, allergy, IBS).
  • Linkage with all available sources of medical record information (inpatient registry, cancer registry, and when possible, through primary care records).
  • Collection of DNA and serum/plasma from all members of the cohort at initiation.
  • Collection of other tissues (whole blood, serum/plasma, CSF, skin biopsies, etc.) as specific research questions dictate.

General Information

General Design

Study design: 
Cohort study
Recruitment target: 
Families (including twin studies, sibships and family based birth cohorts)
Target number of participants: 
200 000
Target number of participants with biological samples: 
200 000
Supplementary information about target number of participants: 

The LifeGene study collects the following biospecimens at baseline: 

  • Blood: 7800 participants in 2013
  • Serum: 2000 participants in 2013
  • Plasma: 7800 participants in 2013 
  • Urine: 5800 participants in 2013

Supplementary Information


Enrollment is ongoing (2010 to 2016-2018). The focus of the LifeGene study covers a wide spectrum of diseases such as:

  • Certain infectious and parasitic diseases (A00-B99)    
  • Neoplasms (C00-D48)    
  • Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)    
  • Endocrine, nutritional and metabolic diseases (E00-E90)    
  • Mental and behavioural disorders (F00-F99)    
  • Diseases of the nervous system (G00-G99)    
  • Diseases of the eye and adnexa (H00-H59)    
  • Diseases of the ear and mastoid process (H60-H95)    
  • Diseases of the circulatory system (I00-I99)    
  • Diseases of the respiratory system (J00-J99)    
  • Diseases of the digestive system (K00-K93)    
  • Diseases of the skin and subcutaneous tissue (L00-L99)    
  • Diseases of the musculoskeletal system and connective tissue (M00-M99)    
  • Diseases of the genitourinary system (N00-N99)    
  • Pregnancy, childbirth and the puerperium (O00-O99)    
  • Certain conditions originating in the perinatal period (P00-P96)    
  • Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)

Number of incident cases not available [Feb 2015]; number of prevalent cases can be provided upon specific request to the study contact.